

Paricalcitol is an active Vitamin D2 analog for the Pharmaceutical industry. Paricalcitol is used for the treatment and prevention of secondary hyperparathyroidism associated with chronic kidney disease (CKD). It has been shown to reduce parathyroid hormone levels by inhibiting its synthesis and secretion.

CARBOGEN AMCIS manufactures this API under cGMP regime at its HIPO manufacturing facilities in Veenendaal, the Netherlands.

Specification: Chemical name: Paricalcitol; 19-NOR-1, 25-dihydroxyergocalciferol; 19-NOR-1, 25-

dihydroxy D2 Content Paricalcitol (HPLC) is 97.0-103.0%

CAS 131918-61-1

CAS no. 131918-61-1

Toxic classification: Very toxic (category T+). Before handling this substance, read the special directions on

the label and Safety Data Sheet (available upon request).

Regulatory: DMF available. An ASMF has been filed and accepted in several European countries.

Application: Pharmaceutical industry. Suitable for drug formulation including tablets, injectables, oral

solutions and soft gel capsules.







CARBOGEN AMCIS B.V.
Nieuweweg 2a, 3901 BE Veenendaal
The Netherlands
Tel: +31 318 545 754
rene.vanoosten@carbogen-amcis.com
www.carbogen-amcis.com

CARBOGEN AMCIS is a leading service provider, offering a portfolio of drug-development and commercialization services to the pharmaceutical and biopharmaceutical industry at all stages of drug development. The integrated services provide innovative chemistry solutions to support timely and safe drug development allowing customers to make the best use of available resources. CARBOGEN AMCIS is also active in the marketing/sales and manufacture of Vitamin D analogues, Vitamin D, Cholesterol and lanolin related products for key markets as pharmaceutical, cosmetic, food, feed as well as industry applications.

CARBOGEN (word), AMCIS (word), CARBOGEN AMCIS (word) and AG (logo) are trademarks owned or licensed by Dishman Carbogen Amcis Limited and all rights are reserved.